Dual antiplatelet therapy may lead to hemorrhagic complications in vitrectomy of proliferative diabetic retinopathy
- 71 Downloads
I read with great interest the distinguished article by Meillon et al. “Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients” . The authors concluded that these drugs should be considered safe regarding hemorrhagic complications during vitreoretinal surgeries. Although valid in many cases, this may not be applicable in diabetics who need vitreoretinal surgery for complications of proliferative diabetic retinopathy (DR) while receiving dual antiplatelet therapy (DAPT) for recently placed coronary stents. As the authors discussed, currently there is no established consensus about the perioperative management of antiplatelet therapy (APT) in patients with coronary stents. There are some arguments against applying the conclusion of this study to these patients. First, only 12 out of 804 patients were receiving DAPT. Second, the type of vitreoretinal surgeries in these 12 patients was not specified; the...
Compliance with ethical standards
The patient has consented to the submission of the letter to the journal.
Conflict of interest
The author declares that there is no conflict of interest.